# Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC

> **NCT05798663** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Alliance Foundation Trials, LLC.** · enrollment: 178 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Tiragolumab

## Key facts

- **NCT ID:** NCT05798663
- **Lead sponsor:** Alliance Foundation Trials, LLC.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-07
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 178 (ESTIMATED)
- **Last updated:** 2026-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05798663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05798663, "Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05798663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*